Stockscreener 앱 받기
4.85
2.81%
-0.14
전일 마감가:
$4.99
열려 있는:
$5.05
하루 거래량:
246.42K
Relative Volume:
0.11
시가총액:
$168.58M
수익:
-
순이익/손실:
$-42.05M
주가수익비율:
-1.7199
EPS:
-2.82
순현금흐름:
$-35.26M
1주 성능:
+7.78%
1개월 성능:
-17.09%
6개월 성능:
+134.30%
1년 성능:
+77.01%
1일 변동 폭
$4.68
$5.08
1주일 범위
$4.38
$5.26
52주 변동 폭
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
4.85 | 168.58M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-10 | 재개 | Guggenheim | Buy |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
Exclusive Healthcare Insights: Protara Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Down 13.7% in January - MarketBeat
Protara Therapeutics (NASDAQ:TARA) vs. Cardiff Oncology (NASDAQ:CRDF) Head-To-Head Review - Defense World
Geode Capital Management LLC Purchases 29,514 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Highlights Recent Updates and Anticipated 2025 Milestones - The Manila Times
Protara Reports 72% Complete Response Rate in TARA-002 Cancer Trial, Secures $100M Funding - StockTitan
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
XTX Topco Ltd Buys New Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Velan Capital Investment Management LP Increases Stake in Protara Therapeutics Inc - GuruFocus.com
Flatiron-based drug company raises $100M for cancer treatment - Crain's New York Business
Protara Therapeutics: Rising From The Ashes (NASDAQ:TARA) - Seeking Alpha
Protara Therapeutics Raises $100M in Stock Offering - TipRanks
Protara Announces Closing of $100 Million Public Offering - GlobeNewswire
SEC Form 424B5 filed by Protara Therapeutics Inc. - Quantisnow
Protara Therapeutics Secures Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Therapeutics: Carving New Roads In Bladder Cancer (TARA) - Seeking Alpha
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst - Seeking Alpha
Protara announces public offering to fund clinical programs By Investing.com - Investing.com Canada
Protara Therapeutics drops 6%, prices $100M offering - MSN
Protara Announces Pricing of $100 Million Public Offering - citybiz
Protara Therapeutics Launches Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Announces Proposed Public Offering - The Manila Times
Protara announces public offering to fund clinical programs - Investing.com
Protara Therapeutics Launches Public Offering to Advance TARA-002 Clinical Development - StockTitan
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes - MSN
HC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA) - Defense World
Protara Therapeutics (STU:1KPA) Enterprise Value : €42.66 Mil (As of Dec. 07, 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Guggenheim - MarketBeat
Protara Therapeutics' (TARA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most - Yahoo Finance
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy - Yahoo Finance
Protara, CG Oncology Tout Promising Bladder Cancer Outcomes - BioSpace
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga
Protera Therapeutics stock remains Buy-rated after promising TARA-002 Phase II results - Investing.com Canada
Protara cell therapy impresses in non-muscle invasive bladder cancer - FirstWord Pharma
TARA stock soars to 52-week high, touches $9.45 amid robust gains - Investing.com Australia
TARA-002 shows promise in bladder cancer trial By Investing.com - Investing.com South Africa
Protara shares spike after cell therapy shows high response rate, no severe side effects in bladder cancer trial - Fierce Biotech
Protara Therapeutics (FRA:1KPA) EV-to-Revenue : (As of Dec. 05, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 55.72 (As of Dec. 05, 2024) - GuruFocus.com
Stock market news: Arcadia Biosciences +186.66%, Protara Therapeutics +101.69% among top gainers during mid day trading - Business Upturn
Protara, CG climb bladder ladder with SUO cancer findings - BioWorld Online
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday? - Benzinga
Stock market today: Arcadia Biosciences +153.62%, Protara Therapeutics +133.20% among top gainers in early trading - Business Upturn
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.53%
자본화:
|
볼륨(24시간):